On Monday 17th of November, at the LSX Investival 2025 and at the start of the Jeffries week in London, Dr Nat Hastings (CEO) and Dr Peter Bach (Head of Drug Development) of Cellestial Health have officially opened the Seed fundraise.
This follows on from a strong year post-Pre-Seed funding, featuring:
✦ Proof-of-concept studies in disease-relevant models
✦ New academic and charity collaborations
✦ Established pipeline for drug development activities
✦ World-class, commercially-oriented senior management team
✦ Biomarker strategy refinement
✦ Established company profile
𝘞𝘩𝘢𝘵 𝘸𝘪𝘭𝘭 𝘵𝘩𝘦 𝘧𝘶𝘯𝘥𝘴 𝘦𝘯𝘢𝘣𝘭𝘦?
The funding will allow for completion of the preclinical development of the first disease-modifying small molecule drug asset for Parkinson’s.
𝘞𝘩𝘢𝘵 𝘪𝘴 𝘵𝘩𝘦 𝘊𝘦𝘭𝘭𝘦𝘴𝘵𝘪𝘢𝘭 𝘱𝘳𝘰𝘱𝘰𝘴𝘪𝘵𝘪𝘰𝘯?
✦ Small molecule therapeutic asset(s)
✦ Protection of astrocytic networks – the essential half of the brain overlooked by traditional therapies
✦ Reduced progression of Parkinson’s – the fastest-growing neurological condition in the world with no cure
✦ Scope for expansion to other astrocytic targets and neurological indications
✦ Patient-led approach to the target product profile design
𝘞𝘩𝘢𝘵 𝘪𝘴 𝐧𝐨𝐭 𝘢 𝘱𝘢𝘳𝘵 𝘰𝘧 𝘊𝘦𝘭𝘭𝘦𝘴𝘵𝘪𝘢𝘭 𝘱𝘳𝘰𝘱𝘰𝘴𝘪𝘵𝘪𝘰𝘯?
✦ It is 𝐧𝐨𝐭 an AI / computational-led platform – Cellestial is leading a 𝘣𝘪𝘰𝘭𝘰𝘨𝘺-𝘧𝘪𝘳𝘴𝘵 platform approach to identify targets and indications, although we will incorporate state-of-art methods, including computational, in our drug R&D
✦ It is 𝐧𝐨𝐭 a new method for small molecule drug generation – we use industry-leading, established and de-risked methods
For all questions regarding this funding round, please contact Cellestial via this LinkedIn page or direct enquiries to info@cellestialhealth.com
𝘍𝘰𝘳 𝘱𝘳𝘰𝘧𝘦𝘴𝘴𝘪𝘰𝘯𝘢𝘭 𝘪𝘯𝘷𝘦𝘴𝘵𝘰𝘳𝘴 𝘰𝘯𝘭𝘺. 𝘔𝘪𝘯𝘪𝘮𝘢𝘭 𝘪𝘯𝘷𝘦𝘴𝘵𝘮𝘦𝘯𝘵 𝘤𝘢𝘱 𝘮𝘢𝘺 𝘢𝘱𝘱𝘭𝘺.
Leave a Reply